No Data
Yifan Pharmaceutical: 2024 Annual Performance Forecast
Yifan Pharmaceutical (002019.SZ): Projected profit for the year 2024 is 0.376 billion yuan to -0.52 billion yuan, turning losses into profits year-on-year.
On January 23, Gelonghui reported that Yifan Pharmaceutical (002019.SZ) announced its performance forecast for 2024, expecting a net income attributable to shareholders of the listed company to be between 0.376 billion yuan and 0.52 billion yuan, marking a turnaround from loss to profit year-on-year; the net income after excluding non-recurring gains and losses is estimated to be between 0.238 billion yuan and 0.356 billion yuan; and the EPS is projected to be between 0.31 yuan/share and 0.43 yuan/share. In 2024, the company anticipates an increase in sales volume of both new and existing proprietary pharmaceutical products (including imports), resulting in higher gross profit. The company's asset impairment losses in 2024 are expected to significantly decrease compared to the previous year.
Shareholders in Yifan Pharmaceutical (SZSE:002019) Have Lost 41%, as Stock Drops 4.3% This Past Week
Yifan Pharmaceutical (002019.SZ): Ryzneuta's marketing authorization application has been approved by ANVISA.
Gelonghui, December 20th丨Yifan Pharmaceutical (002019.SZ) announced that the company recently learned through the "Official Gazette of the Federal Government of Brazil (Diário Oficial da União)" that its product, Abegrin α injection (internal development code: F-627, referred to as "Ryzneuta"), has received approval for marketing authorization, permitting its sale in Brazil.
Yifan Pharmaceutical Gets Registration Approval of Ointment in Singapore
Yifan Pharmaceutical (002019.SZ): The anti-itch ointment has received registration approval in Singapore.
On December 16, Gelonghui reported that Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary SciGen Pte. Ltd. recently received the registration approval for Chinese Patent Medicine issued by the Health Sciences Authority (HSA) of Singapore, allowing the company to exclusively market its anti-itch ointment in Singapore. The anti-itch ointment's main functions are to clear heat and eliminate dampness, dispel wind, and relieve itching. It is used as an adjunct treatment for acute and subacute eczema cases associated with damp-heat or damp obstruction.
Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Share Price Not Quite Adding Up